Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · IEX Real-Time Price · USD
38.52
-0.71 (-1.81%)
Dec 5, 2022 4:00 PM EST - Market closed
-1.81%
Market Cap 2.60B
Revenue (ttm) 345,000
Net Income (ttm) -184.02M
Shares Out 58.53M
EPS (ttm) -6.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 557,587
Open 39.3
Previous Close 39.23
Day's Range 37.97 - 39.3
52-Week Range 6.51 - 39.78
Beta n/a
Analysts Buy
Price Target 49.73 (+29.1%)
Earnings Date Nov 10, 2022

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
IPO Date Jan 7, 2022
Employees 237
Stock Exchange NASDAQ
Ticker Symbol AMLX
Full Company Profile

Financial Performance

In 2021, AMLX's revenue was $285,000, a decrease of -56.15% compared to the previous year's $650,000. Losses were -$87.93 million, 108.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is 49.73, which is an increase of 29.10% from the latest price.

Price Target
$49.73
(29.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual Hea...

1 week ago - Business Wire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Other symbols: BIIB
2 weeks ago - Investors Business Daily

Stocks moving after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, Airbnb

Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.

Other symbols: ABNBAZO
3 weeks ago - Yahoo Finance

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.

3 weeks ago - Business Wire

NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass. , Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Other symbols: NRSN
1 month ago - PRNewsWire

Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common ...

1 month ago - Business Wire

Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock.

1 month ago - Business Wire

Amylyx Pharmaceuticals Announces Launch of Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Launch of Public Offering.

2 months ago - Business Wire

FDA approves new ALS drug that costs $158,000 a year

Amylyx Pharmaceuticals Inc.'s AMLX, -1.13% new treatment for amyotrophic lateral sclerosis just received approval in the U.S., but it's already facing questions about effectiveness and price.

2 months ago - Market Watch

Amylyx (AMLX) Secures the FDA's Approval for ALS Drug

Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.

2 months ago - Zacks Investment Research

Amylyx Shows FDA Can Be Flexible on Drugs for Diseases With Few Treatments

Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive.

2 months ago - Barrons

AMLX Stock Alert: Amylyx Pharma Gains on Huge FDA Win

Shares of Amylyx Pharmaceuticals (NASDAQ: AMLX ) stock were up as much as 10% in premarket trading today on news that the U.S. Food and Drug Administration (FDA) has approved its treatment of the deadly...

2 months ago - InvestorPlace

Amylyx prices newly approved ALS drug at $158,000 per year

Amylyx Pharmaceuticals Inc said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United Sta...

2 months ago - Reuters

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS in Adults.

2 months ago - Business Wire

IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle

After a long road, Amylyx Pharmaceuticals won FDA approval for its ALS treatment late Thursday, leading AMLX stock to surge. The post IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Lon...

2 months ago - Investors Business Daily

Amylyx's ALS Drug Is Approved by the FDA

The drug is the first that the Food and Drug Administration has approved for ALS, also known as Lou Gehrig's disease, in five years.

2 months ago - Barrons

Amylyx's ALS drug wins FDA approval despite questionable data

WASHINGTON — A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government re...

2 months ago - Market Watch

U.S. FDA approves Amylyx ALS drug

The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

2 months ago - Reuters

3 IPO Stocks That You Want to Own

This down market is giving us some really intriguing stocks at cheap prices.

Other symbols: DCGOHLVX
2 months ago - The Motley Fool

Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial are now available in the PRO-ACT database.

2 months ago - Business Wire

Andreas Halvorsen Curbs Amylyx Pharmaceuticals Stake After ALS Drug Gets Committee's Approval

The experimental treatment was recently backed by an FDA advisory committee

2 months ago - GuruFocus

This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?

Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.

2 months ago - The Motley Fool

Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Comp...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals today announced the publication of preclinical data.

2 months ago - Business Wire

Does a Revolutionary New ALS Drug Make This Biotech Stock a Buy Now?

The FDA will most likely approve this company's first drug, but what comes next is more difficult to predict.

2 months ago - The Motley Fool